Navigation Links
The Lancet Publication Of LAPLACE-TIMI 57 And MENDEL Studies Showed AMG 145 Significantly Reduced LDL Cholesterol
Date:11/6/2012

ity lipoprotein (non-HDL-C), apolipoprotein B (ApoB), total cholesterol (TC)/HDL-C ratio and ApoB/ApoA1 ratio.

MENDEL Study Design
MENDEL (Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Patients Currently Not Receiving Drug Therapy For Easing Lipid Levels) is a Phase 2 randomized, multi-center, double-blind, controlled trial designed to evaluate the efficacy, safety and tolerability of AMG 145 in 406 patients with low cardiovascular risk (LDL-C > 100 mg/dL and < 190 mg/dL) who were not receiving statin therapy. AMG 145 was evaluated across nine treatment groups, including AMG 145 at 70 mg, 105 mg and 140 mg dosed Q2W compared to placebo Q2W; and AMG 145 at 280 mg, 350 mg and 420 mg dosed Q4W compared to placebo Q4W; or daily ezetimibe 10 mg. The primary endpoint was percentage change from baseline in LDL-C, measured by preparative ultracentrifugation, at week 12. Secondary efficacy endpoints included the absolute change from baseline in LDL-C at week 12 and the percentage changes from baseline at week 12 in non-high-density lipoprotein (non-HDL-C), apolipoprotein B (ApoB), total cholesterol (TC)/HDL-C ratio and ApoB/ApoA1 ratio.

Webcast Information
Amgen will hold an analyst/investor event on Tuesday, Nov. 6, at 7:00 p.m. Pacific Standard Time to discuss data presented at AHA. A webcast of the event can be found on Amgen's website at www.amgen.com, under Investors. The audio webcast will be archived and available for replay for at least 72 hours.

About AMG 145
AMG 145 is a fully human monoclonal antibody directed against proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that reduces the liver's ability to remove LDL-C from the blood and thereby causes bad cholesterol to increase. AMG 145, developed by Amgen scientists, binds to PCSK9 circulating in the blood and prevents PCSK9 from binding to
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Results For Phase 2b Trial Of Unique Investigational Cell-Based Therapy In Venous Leg Ulcers Published In The Lancet
2. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
3. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
4. Aethlon Medical (AEMD) Note: Cancer Treatment Publication Authored by Aethlon Medical Researchers Now Available
5. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
6. Publication of PrEP Trial Data Provides Clear Evidence that PrEP Works for Men and Women
7. Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting
8. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
9. Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
10. International Spine Products Manufacturer Featured in Upcoming US Business Executive Publication - www.gsmedicalusa.com
11. Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 /CNW/ - On Aug. ... , the Canadian Medical Association (CMA) voted on ... any plant material, including medicinal cannabis. Bedrocan Cannabis Corp., ... supportive of the CMA motion. The CMA ... particular hazards associated with smoking any plant material, including ...
(Date:8/22/2014)... Aug. 22, 2014 Research and Markets ... Research Products: Opportunities, Tools & Technologies" report to ... stem cell research products or you wish to expand ... lucrative this market is. The authors know you want ... effectively to scientists, to generate improved revenues and take ...
(Date:8/22/2014)... Mich. , Aug. 22, 2014  Dr. ... Who with the Diamond Lifetime Achievement Award in the ... as CEO of Cardiovascular Clinical Associates. Dr. ... in managing all major aspects of the business; overseeing ... well as primary coronary intervention. In addition, he is ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2
... CARLSBAD, Calif., Oct. 18 Excaliard Pharmaceuticals, Inc. ... as Chairman of its Board of Directors. Mr. ... years of experience in successfully developing and commercializing ... field.  Excaliard Pharmaceuticals, Inc. is a biotechnology company ...
... Bend Research Inc. ( www.bendres.com ), a ... announced today it has extended its drug discovery ... Company ( www.bms.com ) (NYSE: BMY ... Under the terms of the 3-year agreement, Bristol-Myers ...
Cached Medicine Technology:Excaliard Pharmaceuticals Appoints Thomas Wiggans to Chairman of the Board 2Bend Research Announces Extension of Drug-Discovery Enablement and Development Services Agreement With Bristol-Myers Squibb 2
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- Many Americans know little ... the possibility of an outbreak in the United States, a ... they are worried that there will be a major Ebola ... they or an immediate family member will get sick with ... latest Harvard School of Public Health poll. However, those ...
(Date:8/22/2014)... York (PRWEB) August 22, 2014 ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in uterine surgeries continues ... Massachusetts insurance companies have decided to limit coverage ... the Worcester Telegram, Blue Cross-Blue Shield of Massachusetts ... surgeries that involve morcellation as of September 1, ...
(Date:8/22/2014)... Millennium Treatment Group, a drug ... recently launched a new website. Patients, parents, loved ... now find Millennium Treatment Group at http://www.millenniumtreatmentgroup.com ... at the beginning of July. Everything anyone would ... found on the website. There’s an About Us ...
(Date:8/22/2014)... Vegas, NV (PRWEB) August 22, 2014 ... by Kevin Richardson to restore his own vision from legally ... Shane Michaels, prompting an investigative review. , “There is ... glasses or contacts for everyday function, and most people just ... resort to corrective eye surgery that can be pretty risky ...
(Date:8/22/2014)... Beat Eczema , Susan Clark’s best-selling ... methods to completely cure the eczema symptoms they have ... Michaels, prompting an investigative review. , “Although eczema ... can still be extremely debilitating and life-altering for those ... and pain that it causes on the skin can ...
Breaking Medicine News(10 mins):Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Millennium Treatment Group Has a New Website 2Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2
... night, Oklahoma Governor Brad Henry vetoed Oklahoma House Bill ... business to conduct research that would kill a human ... risk of death or injury. The Oklahoma House ... Senate failed to follow suit.The bill would have banned ...
... Washington G-2 Reports releases top-10 trends to watch ... Demand for outpatient diagnostic imaging has never ... increase over the next three years. In fact, ... increase by double digits across all modalities (CT, ...
... can help physicians objectively assess a patient,s breast density ... changes that may suggest cancer, according to a study ... of Maryland School of Medicine, Baltimore, MD. ... estimates mammographic breast density. Results obtained by the computer ...
... (VQ) as an alternative to CT for the diagnosis ... patient exposure, according to a study performed at Albert ... NY. "VQ scanning is a nuclear test which shows ... is a pulmonary embolism, the air can enter normally, ...
... breeding techniques, shed light on human genome , , THURSDAY, April ... researchers in 25 countries has succeeded in sequencing the entire ... implications for understanding the biology of this bovine and related ... said the authors of two reports in the April 24 ...
... USA applauds President Obama,s national call for volunteerism and urges ... their local communities. President Obama recently signed a new ... learn about volunteer and service opportunities. "We need your service ... not going to tell you what your role should be. ...
Cached Medicine News:Health News:Demand for Outpatient Diagnostic Imaging Forecast to Increase by Double Digits Across All Modalities Through 2012 2Health News:New computer algorithm helps physicians determine and monitor breast density 2Health News:Scientists From 25 Countries Sequence Cow Genome 2Health News:Scientists From 25 Countries Sequence Cow Genome 3Health News:YWCA USA Applauds President Obama's National Call for Volunteer Service 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: